Payment overview · 2025
General Payments
$401.23
23 reported records · 10 companies
Healthcare provider profile · identity verified
Nedal Adi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WEBSTER, TX · NPI 1093102477
Verified facts
What the public records show
CMS Open Payments records show Nedal Adi, M.D. received $401.23 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $105.92 | 26.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.19 | 23.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.64 | 11.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.13 | 10.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.77 | 7.7% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.23 | 4.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.98 | 4.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.76 | 4.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.76 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.85 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $401.23 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $59.05 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $59.05 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $47.61 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.53 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.13 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 24 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 100 |
| Gabapentin | Gabapentin | 290 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 80 |
| Losartan Potassium | Losartan Potassium | 242 | 88 |
| Lisinopril | Lisinopril | 230 | 74 |
| Furosemide | Furosemide | 216 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 47 |
| Metformin Hcl | Metformin Hcl | 150 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 49 |
| Eliquis | Apixaban | 144 | 33 |
| Omeprazole | Omeprazole | 141 | 57 |
| Sertraline Hcl | Sertraline Hcl | 139 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 41 |
| Trazodone Hcl | Trazodone Hcl | 133 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 44 |
| Metformin Hcl Er | Metformin Hcl | 114 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 41 |
| Allopurinol | Allopurinol | 90 | 25 |
| Carvedilol | Carvedilol | 88 | 29 |
| Ozempic | Semaglutide | 88 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 42 |
| Potassium Chloride | Potassium Chloride | 79 | 27 |
| Farxiga | Dapagliflozin Propanediol | 76 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 16 |
| Montelukast Sodium | Montelukast Sodium | 73 | 23 |
| Meloxicam | Meloxicam | 72 | 25 |
| Simvastatin | Simvastatin | 71 | 21 |
| Tramadol Hcl | Tramadol Hcl | 70 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 22 |
| Memantine Hcl | Memantine Hcl | 61 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 20 |
| Mirtazapine | Mirtazapine | 59 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 23 |
| Donepezil Hcl | Donepezil Hcl | 55 | 18 |
| Nifedipine Er | Nifedipine | 53 | 13 |
| Linzess | Linaclotide | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 18 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | 13 |
| Januvia | Sitagliptin Phosphate | 48 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Spironolactone | Spironolactone | 48 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 16 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 36 |
| Glipizide | Glipizide | 45 | 13 |
| Methylprednisolone | Methylprednisolone | 45 | 42 |
| Alendronate Sodium | Alendronate Sodium | 42 | 17 |
| Azelastine Hcl | Azelastine Hcl | 41 | 19 |
| Azithromycin | Azithromycin | 41 | 41 |
| Finasteride | Finasteride | 41 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 14 |
| Valsartan | Valsartan | 39 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Methocarbamol | Methocarbamol | 35 | 21 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 34 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 14 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | 11 |
| Temazepam | Temazepam | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 21 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 14 |
| Famotidine | Famotidine | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Primidone | Primidone | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.23 · 23 records | Amgen Inc. | AREXVY, BEXSERO, CAPVAXIVE, CONTRAVE, EVENITY, INSPIRE, KRYSTEXXA, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PEDIARIX, PROLIA, REPATHA, ROTARIX, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error